AOD-9604 Adolescent (12, 17) Dosing: What Clinicians and Parents Need to Know

What Is AOD-9604 and Why Is It Being Asked About in Adolescents?

AOD-9604 is a synthetic peptide corresponding to amino acids 176, 191 of human growth hormone (hGH). Researchers isolated this C-terminal fragment specifically because it appeared to stimulate lipolysis in adipose tissue without activating the full GH receptor, raising hopes for a weight-management compound with fewer systemic GH side effects. Interest in adolescent use has grown alongside the broader pediatric obesity crisis: the CDC reports that 19.7% of U.S. children and adolescents aged 2, 19 were affected by obesity as of 2017 to 2020, placing enormous pressure on clinicians to find solutions beyond lifestyle modification alone [1].

That pressure, however, does not create evidence. AOD-9604 was studied in adult clinical trials through the early 2000s under the sponsor Metabolic Pharmaceuticals, and those trials ultimately did not lead to regulatory approval [2]. The compound was granted GRAS (Generally Recognized as Safe) status by the FDA for use as a food ingredient at low oral doses, but that designation carries no therapeutic implication and does not extend to injectable subcutaneous use in any population [3]. Prescribers sourcing AOD-9604 for patients today are working exclusively within the 503A compounding pharmacy framework, which permits individualized preparations but does not confer approval or validated dosing guidance [4].

The adolescent age window (12, 17) is biologically distinct from adulthood in ways that matter directly for any peptide acting on or near the GH axis. Growth plates remain open in most adolescents until mid-to-late puberty; endogenous GH pulsatility is at its lifetime peak; and the hypothalamic-pituitary-gonadal axis is actively reorganizing [5]. Any exogenous agent with structural homology to hGH deserves scrutiny in this context, even if its receptor-binding profile differs from intact GH.

How AOD-9604 Works: The Lipolysis Mechanism

The fragment 176, 191 retains the lipolytic region of hGH but lacks the receptor-binding domain responsible for anabolic and mitogenic effects. Heffernan et al. (Endocrinology, 2001) demonstrated in obese rodent models that AOD-9604 stimulated fat breakdown and inhibited lipogenesis without producing measurable changes in IGF-1 concentrations or causing the glucose intolerance associated with full-length GH administration [6]. That study used intraperitoneal dosing in mice and rats and cannot be directly translated to subcutaneous dosing in human adolescents.

The proposed mechanism involves beta-3 adrenergic receptor stimulation and enhanced fatty acid oxidation in adipocytes [6]. Whether this pathway operates identically in adolescent adipose tissue, which carries a higher proportion of brown adipose tissue relative to adult depots, remains unstudied [7]. The rodent data are important background, but they represent the beginning of an evidence chain, not the end of one.

No published mechanistic study has examined how the fragment interacts with growth-plate chondrocytes, hypothalamic GHRH neurons, or pubertal steroidogenesis. That absence of data is not reassurance. The National Institutes of Health emphasizes that absence of evidence is not evidence of absence when evaluating novel compounds in pediatric populations [8].

Current Evidence Base: What Trials Actually Exist

The honest answer is that no published randomized controlled trial has examined AOD-9604 dosing, efficacy, or safety in humans aged 12, 17. The adult trial record is itself limited.

Metabolic Pharmaceuticals conducted several Phase 2 trials in the early 2000s testing oral and intranasal AOD-9604 in overweight adults. These trials showed modest and inconsistent weight-loss results, and the program was discontinued before Phase 3 completion [2]. No pediatric extension was conducted. A search of ClinicalTrials.gov under "AOD-9604" returns no active or completed trials in the adolescent age group as of mid-2025 [9].

For comparison, the FDA-approved pediatric weight-management agents have substantially more strong trial records. The SCALE TEENS trial (N=251, ages 12, 17) showed that liraglutide 3 mg once daily produced a 4.5 percentage-point greater reduction in BMI z-score than placebo at 56 weeks [10]. The STEP TEENS trial (N=201, ages 12, 17) demonstrated that semaglutide 2.4 mg once weekly reduced BMI by 16.1% versus a 0.6% increase with placebo at 68 weeks [11]. These approved agents have 12-month pediatric safety datasets; AOD-9604 has none.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Pharmacological treatment of obesity in adolescents should use agents with demonstrated safety and efficacy in randomized trials conducted in this age group" [12]. AOD-9604 does not meet that standard.

Regulatory and Compounding Status

AOD-9604 is not approved by the FDA as a drug product for any indication [3]. Its availability in clinical practice depends entirely on the 503A compounding exemption under the Federal Food, Drug, and Cosmetic Act, which allows licensed compounding pharmacies to prepare individualized prescriptions for specific patients [4]. This pathway exists to serve patients with documented medical needs that cannot be met by commercially available products. It is not a regulatory approval mechanism.

Prescribing AOD-9604 to an adolescent via a 503A compounder means the prescriber bears full clinical and legal responsibility for that decision. The pharmacy may prepare the compound in a sterile subcutaneous formulation, typically at concentrations of 1 to 5 mg/mL, but it does not validate safety or efficacy. The FDA has previously sent warning letters to compounders promoting peptides including BPC-157, TB-500, and related research compounds as therapeutic agents, signaling regulatory scrutiny of the broader peptide compounding space [13].

Prescribers should also be aware that the American Academy of Pediatrics policy statement on off-label prescribing recommends that clinicians "use the best available evidence, inform families clearly about the off-label nature of the treatment, and document the clinical rationale thoroughly" [14]. Applying that standard to AOD-9604 in adolescents requires acknowledging that the evidence base consists of a single rodent study as its primary source.

Adult Dosing Context and Why It Cannot Simply Be Scaled Down

In adult compounding practice, AOD-9604 is typically prescribed at 250 to 500 mcg subcutaneously once daily, administered in a fasted state 30 minutes before the first meal or before exercise. Some protocols use 300 mcg once daily for 12 to 24 weeks. These figures derive from extrapolations of the Metabolic Pharmaceuticals adult trial data and clinical experience at peptide-specialty practices, not from controlled dose-finding studies [2].

Pediatric pharmacokinetics differ from adult pharmacokinetics in ways that make simple weight-based scaling unreliable. Adolescents have proportionally higher total body water, different renal clearance rates that vary significantly across Tanner stages, and hepatic enzyme expression patterns that continue maturing into the mid-20s [15]. A dose that produces a given plasma concentration in a 40-year-old will not produce the same concentration in a 14-year-old of the same body weight. The FDA's pediatric drug development guidance specifically requires dedicated pediatric pharmacokinetic studies before dosing recommendations can be made for new molecular entities in patients under 18 [16]. Those studies have never been conducted for AOD-9604.

Body weight-based dosing (mcg/kg) is sometimes proposed in peptide compounding circles, but no published study supports any specific mcg/kg target for AOD-9604 in adolescents. Applying an adult dose of 300 mcg to a 50 kg adolescent would yield 6 mcg/kg, a ratio that has no validation whatsoever in this age group.

Growth, Puberty, and GH-Axis Considerations

Adolescence is the developmental window most sensitive to perturbations of the GH/IGF-1 axis. Endogenous GH secretion peaks during puberty, with nocturnal GH pulses reaching amplitudes 2, 3 times higher than adult levels, driving the pubertal growth spurt and mediating changes in body composition [17]. The hypothalamic-pituitary axis is actively calibrated during this period by sex steroids, leptin, ghrelin, and multiple other signals [17].

AOD-9604 is described as acting independently of the GH receptor, and the Heffernan et al. animal data showed no IGF-1 change [6]. Those findings, however, were generated in non-pubertal obese adult rodent models. The pubertal GH axis in a 13-year-old human involves feedback loops and receptor dynamics that were not represented in those experiments. At present, there is no data showing that AOD-9604 is growth-plate neutral in a pubertal primate model, let alone in human adolescents.

Clinicians who do prescribe AOD-9604 in this age group under a documented informed-consent framework should, at minimum, measure standing height and sitting height every 3 months, track height velocity against population norms, assess Tanner stage at each visit, and obtain fasting IGF-1 and IGFBP-3 levels at baseline and every 3 months [18]. Any decrease in height velocity below 4 cm/year in a mid-pubertal patient should prompt immediate discontinuation and endocrinology referral [18].

Mental Health and Weight Stigma Monitoring

The AAP's 2023 Clinical Practice Guideline for Obesity Treatment in Children and Adolescents places mental health screening at the center of any pharmacological obesity intervention [19]. Adolescents with obesity face substantially elevated rates of depression, anxiety, and disordered eating. The guideline explicitly states: "Clinicians should screen for depression, anxiety, and disordered eating behaviors before initiating and during pharmacotherapy for obesity in adolescents" [19].

This requirement applies regardless of the agent being used. A patient who presents for AOD-9604 as a perceived "milder" or "more natural" alternative to approved GLP-1 receptor agonists is still a patient who needs a validated depression screen (PHQ-A for adolescents), an Eating Disorder Examination Questionnaire, and a conversation about body image expectations. Weight loss interventions that are not embedded in a behavioral health framework carry documented risks of worsening eating disorder pathology in teenagers [20].

Prescribers should also document the conversation about FDA-approved alternatives. Liraglutide 3 mg (Saxenda) carries FDA approval for adolescents 12 and older with an initial BMI at or above the 95th percentile [10]. Semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents 12 and older in December 2022 [11]. Orlistat 120 mg three times daily carries approval for adolescents 12 and older [21]. Each of these has pediatric trial data; AOD-9604 has none.

Proposed Monitoring Framework for Any Prescriber Who Proceeds

Given that some prescribers may proceed with AOD-9604 in adolescents despite the absence of trial data, a minimum monitoring protocol is outlined here. This framework is not an endorsement of the practice. It represents the floor of clinical diligence that informed consent and standard of care would require.

Baseline workup (before first dose): Fasting glucose and HbA1c; fasting insulin and HOMA-IR; IGF-1 and IGFBP-3; complete metabolic panel; lipid panel; standing height, weight, and BMI z-score; Tanner staging by a qualified clinician; PHQ-A depression screen; EDE-Q eating disorder screen; documented informed consent from both patient and parent or guardian specifying the off-label, unapproved nature of the compound.

At 4 weeks: Fasting glucose, injection-site assessment, symptom review, PHQ-A repeat.

At 3 months: Repeat full baseline labs, height measurement and velocity calculation, Tanner reassessment, lipid panel, PHQ-A.

Stopping criteria: Height velocity below 4 cm/year at any mid-pubertal assessment; any new or worsened depressive symptom cluster; fasting glucose above 100 mg/dL without prior impairment; IGF-1 rise above age-adjusted upper limit; any sign of injection-site infection or systemic inflammatory response.

The American Association of Clinical Endocrinologists recommends that weight-management pharmacotherapy in adolescents be managed or co-managed by a clinician with specific pediatric endocrinology or adolescent medicine expertise [22]. This recommendation is particularly apt when the compound in question lacks any pediatric approval or trial data.

Comparing AOD-9604 to Approved Adolescent Weight-Management Options

A direct comparison clarifies the evidentiary gap. The STEP TEENS trial enrolled 201 adolescents aged 12, 17 with obesity (BMI at or above the 95th percentile) and showed that semaglutide 2.4 mg subcutaneous once weekly produced a mean BMI reduction of 16.1% at 68 weeks versus a 0.6% increase in the placebo group (P<0.001) [11]. That trial also tracked height velocity and found no significant difference between semaglutide and placebo groups in linear growth over 68 weeks, providing at least one meaningful safety data point that AOD-9604 simply cannot offer [11].

The SCALE TEENS trial (N=251) tested liraglutide 3 mg daily over 56 weeks and showed a 4.5 percentage-point greater reduction in BMI z-score versus placebo (P<0.001), with documented safety data including gastrointestinal adverse events (72% vs. 46% placebo) and no growth suppression signal [10]. These numbers matter not because GLP-1 agonists are appropriate for every adolescent, but because they represent the minimum evidentiary bar that any agent claiming to address adolescent obesity should eventually clear.

AOD-9604 has not cleared that bar. Prescribers who recommend it over FDA-approved alternatives must document in writing why those alternatives are contraindicated or insufficient for the individual patient.

Dosing Conversations With Adolescent Patients and Families

Adolescent patients aged 12, 17 have meaningful capacity to participate in shared decision-making about their own treatment, and the AAP recommends involving them directly in pharmacotherapy discussions [19]. When a family asks about AOD-9604, the clinical conversation should cover three areas.

First, transparency about the evidence gap. The phrase "not enough data" means something specific here: no human trial in this age group, no safety signal study in pubertal animals, and no pharmacokinetic data to support any dose. Families often hear "research compound" and interpret it as cutting-edge. The reality is the absence of the research that would be needed to prescribe safely.

Second, what monitoring would look like in practice. Monthly visits, quarterly labs, and growth tracking are not trivial commitments. A family should understand before the first injection that any sign of growth-velocity change or mood deterioration ends the trial immediately.

Third, the approved alternatives and why they exist. Showing a family the STEP TEENS forest plot, with BMI reductions of 16.1% in adolescents treated with semaglutide versus essentially zero with placebo, gives them a concrete comparator [11]. FDA approval exists precisely because regulators reviewed that kind of trial data.

Adolescents who decline injectable GLP-1 agonists due to needle burden, who have a documented contraindication, or whose families prefer a different approach may end up in a discussion about AOD-9604. That discussion should never begin with the premise that AOD-9604 is safer or better-studied. It begins with an honest accounting of what is and is not known [8].

Injection Technique and Practical Compounding Considerations

If a prescriber does write an order for AOD-9604 for an adolescent patient within a properly documented informed-consent framework, several practical points apply.

The compound should be sourced only from a 503A-accredited compounding pharmacy with current USP 797 sterile compounding compliance and available certificates of analysis [4]. The prescription should specify the concentration, preservative status, and diluent. AOD-9604 is typically compounded in bacteriostatic water at 1 to 5 mg/mL and stored refrigerated at 2, 8 degrees Celsius after reconstitution; in-use stability beyond 28 days after reconstitution has not been independently validated [4].

Subcutaneous injection technique in adolescents follows standard insulin-injection principles: rotate sites among abdomen, outer thigh, and back of upper arm; use a 29, 31 gauge needle at 90 degrees for adequate subcutaneous tissue; inject in a fasted or near-fasted state to align with proposed metabolic mechanism [6]. Needle phobia is more common in adolescents than adults, and injection training should include both the patient and a caregiver. The CDC's immunization resource on injection technique, while directed at vaccines, provides the clearest publicly available guidance on subcutaneous injection angles and site rotation for adolescent patients [23].

Discard any vial that appears cloudy, discolored, or particulate. Unopened lyophilized powder should be stored at or below minus 20 degrees Celsius per standard peptide handling guidance [4].